COVID-19
The Lancet Respiratory Medicine – Peer-Review: Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
The Lancet Respiratory Medicine – Independent Expert Commentary: Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
Thorax – Peer-Review: : Early lenzilumab treatment of COVID-19 patients using c-reactive protein as a biomarker improves efficacy: results from the phase 3 ‘LIVE-AIR’ trial
Journal of Medical Economics: Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective
ClinicoEconomics and Outcomes Research: Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS
bioRxiv: GM-CSF and Cytokine Storm in Coronavirus
Journal of Translational Medicine: The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome